Document Detail

Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
MedLine Citation:
PMID:  18837739     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recently it has been postulated that gallbladder mucin hypersecretion observed in the pathogenesis of cholesterol gallstone disease may be induced by biliary lipid peroxidation. Ursodeoxycholic acid treatment reduces mucin concentration and the formation of cholesterol crystals in the gallbladder bile of patients with cholesterol gallstones and this effect might be mediated by a decrease of biliary lipid peroxidation. MATERIAL AND METHODS: In a double-blind, placebo-controlled trial patients with symptomatic cholesterol gallstones received either ursodeoxycholic acid (750 mg daily) (n = 10) or placebo (n = 12) 10-12 days prior to cholecystectomy. As a marker for lipid peroxidation malondialdehyde was measured in bile together with mucin concentration. In addition, the mucin secretagogue activity of the individual bile samples was assessed in cultured dog gallbladder epithelial cells. RESULTS: Ursodeoxycholic acid therapy resulted in a significant reduction of lipid peroxidation in bile as determined by the biliary malondialdehyde concentration (1.36 +/- 0.28 vs. 2.05 +/- 0.38 micromol L(-1); P < 0.005) and the malondialdehyde (micromol L(-1))/total bile acid (mmol L(-1)) ratio (0.02 +/- 0.005 vs. 0.06 +/- 0.01; P < 0.001). Furthermore, a decrease in mucin concentrations (0.7 +/- 0.3 vs. 1.3 +/- 0.5 mg mL(-1); P < 0.005) and of the mucin secretagogue activity of gallbladder bile (0.9 +/- 0.2 vs. 2.2 +/- 0.3 times control; P < 0.001) was observed. CONCLUSIONS: The reduction of lipid peroxidation and mucin secretagogue activity of gallbladder bile induced by ursodeoxycholic acid treatment may contribute to the beneficial effects of this drug on gallbladder bile composition and symptoms in cholesterol gallstone patients.
C Jüngst; N Sreejayan; B Zündt; I Müller; F W Spelsberg; T P Hüttl; G A Kullak-Ublick; R del Pozo; D Jüngst; C von Ritter
Related Documents :
3943699 - Transformation of chenodeoxycholic acid to ursodeoxycholic acid in patients with crohn'...
978439 - Pharmaceutical applications of solid dispersion systems: dissolution of griseofulvin-su...
5797529 - Bacterial 7-dehydroxylation of cholic acid and allocholic acid.
17053389 - Scintigraphic gallbladder visualization with gangrenous acalculous cholecystitis.
7435569 - Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic ac...
16143129 - Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic chole...
15826079 - Purification and partial characterization of broccoli (brassica oleracea var. italica) ...
11434969 - Biomass production and studies on rhodopseudomonas palustris grown in an outdoor, tempe...
3550789 - Prostaglandin e2 and i2 treatment of acute experimental pancreatitis in rats.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical investigation     Volume:  38     ISSN:  1365-2362     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-10-07     Completed Date:  2008-12-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  634-9     Citation Subset:  IM    
Division of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bile / drug effects,  metabolism*
Cholagogues and Choleretics / pharmacology,  therapeutic use
Double-Blind Method
Gallbladder / secretion*
Gallstones / drug therapy*
Lipid Peroxidation / drug effects*
Middle Aged
Mucins / drug effects*,  secretion
Treatment Outcome
Ursodeoxycholic Acid / pharmacology,  therapeutic use*
Reg. No./Substance:
0/Cholagogues and Choleretics; 0/Mucins; 0/Placebos; 128-13-2/Ursodeoxycholic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of Helicobacter pylori eradication on oncogenes and cell proliferation.
Next Document:  Mild portal endotoxaemia induces subacute hepatic inflammation and pancreatic beta-cell dysfunction ...